IPP Bureau
PM to inaugurate Amrita Hospital and Homi Bhabha Cancer Hospital & Research Centre
By IPP Bureau - August 23, 2022
The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region
PGIMER Satellite Centre to be functional by Jan 2023: Dr. Mandaviya
By IPP Bureau - August 22, 2022
Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Wockhardt signs USFDA approved manufacturing partners
By IPP Bureau - August 22, 2022
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
8th edition of Indo-Japanese Chronic Total Occlusion (IJCTO) summit concluded successfully
By IPP Bureau - August 22, 2022
The summit to demonstrate revolutionary techniques and advanced medical procedures for treating CTO
USFDA grants emergency use authorization for Novavax COVID-19 vaccine
By IPP Bureau - August 22, 2022
Novavax' vaccine is the first protein-based COVID-19 vaccine authorized in the U.S.
Ascletis announces IND approval of Oral RdRp Inhibitor ASC10 for COVID-19 by China NMPA
By IPP Bureau - August 22, 2022
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
DCGI approves AstraZeneca 's Olaparib film-coated tablets
By IPP Bureau - August 20, 2022
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Shilpa Medicare completes clinical studies of high concentration biosimilar Adalimumab
By IPP Bureau - August 20, 2022
The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets
Godrej reveals how to win the war against Malaria through strategic collaboration
By IPP Bureau - August 20, 2022
~96% decline reported in Malaria cases in Madhya Pradesh, due to public-private-people partnership
European Medicines Agency accepts Menarini’s application for Elacestrant
By IPP Bureau - August 20, 2022
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union
Swissmedic approves Kapruvia with additional regulatory decisions expected in H2 2022
By IPP Bureau - August 20, 2022
Therapy recently approved in Canada under the brand name KORSUVA
Merck, Starpharma expand partnership to develop antibody drug conjugates
By IPP Bureau - August 19, 2022
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
WuXi STA breaks ground for second manufacturing facility in US
By IPP Bureau - August 19, 2022
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Strides receives USFDA approval for Naproxen Sodium OTC Softgel capsules
By IPP Bureau - August 19, 2022
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma
Lupin receives approval from U.S. FDA for Rufinamide Tablets USP
By IPP Bureau - August 19, 2022
The product will be manufactured at Lupin's facility in Goa, India.
